This program will outline current methods to identify patients at risk for hereditary colorectal cancer and discuss potential strategies to improve access for genetic testing and treatment for these patients.

1. Review current genetic algorithms for identifying patients at risk hereditary CRC and discuss benefits of simplifying these tools.
2. Examine potential benefits of testing all patients diagnosed with CRC.
3. Identify challenges in testing all patients with CRC and review current models to identify patients with Lynch Syndrome.
4. Evaluate genetic testing strategies for all patients with PDAC compared to patients with CRC.

Presenters:

Heather Hampel, MS, LGC

Matthew B. Yurgelun, MD

This nursing continuing professional development activity is approved for 1.25 contact hours from Oregon Nurses Association (ONA), an accredited approver by the American Nurses Credentialing Center’s Commission on Accreditation (ANCC).  Contact hours will be awarded to participants who view the entire program recording and complete the post-activity survey.

Click here after viewing the webinar to complete the survey:

Take Survey

Please pay close attention to the instructions for receiving your certificate at the end of this survey. Once you have completed this survey in entirety you will have an option to print or save the image of the certificate. We recommend that you complete this from a desktop or your laptop computer for best quality and options for saving this file.

Please read the instructions below carefully to obtain your certificate.

Please right click on the image of the certificate below and select “save as an image”. You can name the file and save to your computer to access later or to print. If you encounter an error message when downloading to your computer, right click the download tab and click “resume”. This should correct this issue.

IMPORTANT: You must save the image at this time to obtain this certificate for your records. Certificates will not be emailed.

***You must complete the webinar and survey no later than March 14, 2024 to claim credit***

Myriad Genetics Lab has approved exemption for commercial interest as a diagnostic laboratory. There are no conflicts of interest with individuals in the position to control content for this activity.